Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Hirota

Dermatology University Place, WA Doctor of Osteopathy

NPI 1144294240 CMS profile 97512

5225 Cirque Dr W, University Place, WA 98467

Open in the dashboard

General payments

$2,365

149 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Hirota of University Place, WA is reported in the CMS Open Payments database as having received $2,365 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $405 32
2024 General $228 17
2023 General $545 33
2022 General $365 20
2020 General $99 5
2019 General $724 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Hirota
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Thomas Hirota were reported at $405. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Thomas Hirota Dermatology median Middle half National median
2019 $724 $454 $129–$1,240 $163
2020 $99 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $365 $514 $143–$1,391 $149
2023 $545 $607 $159–$1,674 $160
2024 $228 $751 $204–$1,903 $164
2025 $405 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $884 65 payments
  2. Novartis Pharmaceuticals Corporation $249 15 payments
  3. Janssen Biotech, Inc. $237 17 payments
  4. Amgen Inc. $168 7 payments
  5. Pfizer Inc. $164 8 payments
  6. Sun Pharmaceutical Industries Inc. $77 3 payments
  7. LEO Pharma Inc. $54 2 payments
  8. Genzyme Corporation $53 3 payments
  9. Organon LLC $51 6 payments
  10. Regeneron Healthcare Solutions, Inc. $51 2 payments
  11. Other $377 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,347 147 payments
  2. Education $18 2 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI Immunology $501 34 payments
  2. TREMFYA $230 16 payments
  3. SKYRIZI Immunology $152 15 payments
  4. HUMIRA $138 9 payments
  5. COSENTYX Dermatology $112 8 payments
  6. Otezla $105 4 payments
  7. EUCRISA $92 5 payments
  8. RINVOQ $83 6 payments
  9. COSENTYX Dermatology $80 4 payments
  10. ILUMYA $77 3 payments
  11. Other $854 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

498

Median for Dermatology: 534

Drug cost

$313,035

Median for Dermatology: $67,151

Branded share of claims

19.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Unoready Pen Secukinumab Brand 12 $139,389
Enbrel Etanercept Brand 13 $95,772
Dupixent Pen Dupilumab Brand 14 $53,139
Ivermectin Generic 15 $5,161
Betamethasone Dipropionate Generic 30 $3,120
Clobetasol Propionate Generic 54 $2,992
Fluorouracil Generic 26 $2,412
Metronidazole Generic 43 $2,234
Tacrolimus Generic 11 $2,050
Azelaic Acid Generic 14 $1,337

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$146,173

Of which drugs: $14,807

Medicare patients

841

Average age 76

Services billed

3,140

299 women, 542 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 39%
Diabetes 25%
Ischemic heart disease 24%
Atrial fibrillation 19%
Chronic kidney disease 18%
Heart failure 15%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $144
$144 — —
CIBINQO
  • PFIZER INC. $26
$26 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $22
$22 12 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $14
$14 — —
RINVOQ
  • AbbVie, Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record